drugset / Trial / NCT04659915

Counteracting Deleterious Metabolic Glucocorticoid Effects With Metformin

NCT04659915 ↗

Phase 4 Completed 19 enrolled Eleonora Seelig
RandomizedCrossoverDouble-blindPrevention

Summary

Supraphysiological doses of glucocorticoids (GCs) are widely prescribed as immunosuppressants and metabolic side effects such as obesity and diabetes are extremely common. Efforts to investigate and prevent these side effects are lacking. The antidiabetic drug metformin was shown in previous studies to prevent deterioration of glucose homeostasis during GC therapy in patients. However, mechanisms of metformin counteracting GC-induced side effects remain poorly understood. In a randomized, placebo-controlled, cross-over study, 18 healthy volunteers will receive a 7-day course of prednisone with metformin or placebo. Established methods will be used to assess systemic changes in energy homeostasis and novel techniques such as metabolomics will identify underlying pathways. This will advance the understanding of energy homeostasis during GC excess, may prevent thousands of patients from GC-induced side effects and also offers a model for targeting disrupted endogenous GCs secretion.

Timeline

Start
2021-02-25
Primary completion
2021-08-18
Completion
2021-08-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 2000 mg Oral
Background Prednisone Other / unclassified 30 mg Oral